Full-Time

Supervisor

Biospecimen Management

Posted on 11/5/2025

Personalis

Personalis

201-500 employees

Specialized cancer genomics sequencing and analysis

Compensation Overview

$42.30 - $52.80/hr

+ Annual performance-based bonus + Long-term incentive units (equity) + Sales incentive plan

Fremont, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Minimum 4 years of experience in a biological laboratory environment; minimum 1 year experience in a Lead role is required.
  • Proficiency in laboratory safety and quality control procedures and regulations.
  • Good understanding of biospecimen accessioning, processing, storage, and shipping protocols.
  • Strong multi-tasking skills and ability to thrive in a fast-paced, deadline-driven environment.
  • Proficient in Microsoft Office Suite and Google Workspace.
  • Strong verbal and written communication skills with the ability to share and receive feedback across all organizational levels.
  • Commitment to teamwork and achieving organizational goals.
  • Customer-focused mindset with a proven track record of exceeding service and quality expectations.
  • Experience working in CLIA-accredited environments is strongly preferred.
  • Associate degree required; Bachelor’s degree preferred.
Responsibilities
  • Supervise staff and oversee all sample management workflows, including accessioning and quality report checks.
  • Ensure timely and accurate data entry into the sample management systems and oversee quality control of specimen data.
  • Ensure compliance with laboratory quality control policies, documenting all activities appropriately.
  • Lead root cause investigations for nonconformances and/or CAPAs, and document corrective actions.
  • Assist in audits and inspections related to biospecimen management and ensure readiness for regulatory and internal audits.
  • Track, compile, and analyze performance metrics to support continuous improvement.
  • Provide regular status updates and progress reports to management, highlighting KPIs, issues, solutions, and areas for improvement.
  • Act as the primary point of contact for team inquiries and communicate updates on new processes.
  • Maintain and organize the Accessioning and Biobank workspace, including sample storage and related equipment.
  • Log and manage data in the LIMS and Clinical Portal.
  • Manage QA/QC processes for cases progressing through the laboratory.
  • Develop and implement new workflows and SOPs to enhance quality, efficiency, and safety in accessioning operations.
  • Collaborate cross-functionally with Project Management, Lab Operations, Genetic Counselors, and Pathologists.
  • Manage complex operational activities independently, exercising strong managerial judgment.
  • Troubleshoot laboratory workflow issues and implement effective solutions.
  • Consistently demonstrate professionalism, leadership, and a solution-oriented approach.
Desired Qualifications
  • Bachelor’s degree preferred.
  • Experience with CLIA-certified laboratory environments strongly preferred.

Personalis provides cancer genomics services, including sequencing and data analysis for pharma, academia, and clinicians. Its NeXT Platform analyzes a tissue sample to generate molecular data across about 20,000 genes, covering tumor and immune features. A key product, NeXT Personal, detects minimal residual disease and cancer recurrence by measuring circulating tumor DNA to guide care. The company aims to enable precise, data-driven cancer treatment and monitoring through integrated sequencing, analysis, and biomarker discovery.

Company Size

201-500

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Medicare coverage for lung cancer, breast cancer enables five-fold clinical revenue growth.
  • 258% Q1 2026 clinical test volume surge to 7,815 tests demonstrates adoption.
  • Tempus exclusive partnership reaches 2,000+ hospitals, accelerating post-reimbursement market penetration.

What critics are saying

  • Q1 2026 revenue declined 25% YoY; clinical ramp must offset biopharma decline.
  • Natera's Signatera captures biopharma contracts with established reimbursement and lower pricing.
  • Private insurer reimbursement delays beyond Medicare stall 171% projected clinical volume growth.

What makes Personalis unique

  • Whole-genome sequencing detects structural variants competitors' targeted panels miss.
  • NeXT Personal tracks 1,800 tumor variants, outperforming Natera's Signatera significantly.
  • Mayo Clinic, Yale, ICR partnerships validate clinical-grade comprehensive cancer genomics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Employee Stock Purchase Plan

Tuition Reimbursement

Paid Vacation

Paid Sick Leave

Commuter Benefits

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 13th, 2026
Personalis debuts Real-Time Variant Tracker to monitor therapy resistance during ctDNA testing at AACR

Personalis, a genomics company specialising in precision oncology, will present data on its NeXT Personal ultrasensitive ctDNA assay at the American Association for Cancer Research Annual Meeting in San Diego from 17–22 April 2026. The company will debut its Real-Time Variant Tracker, a new feature designed to longitudinally track therapy resistance mutations during minimal residual disease testing. An oral presentation will highlight NeXT Personal's use in colorectal cancer, focusing on ultrasensitive ctDNA detection for predicting and tracking response to neoadjuvant immunotherapy. A poster presentation will cover analytical validation and real-world case studies of the Real-Time Variant Tracker, including monitoring ESR1 mutations linked to therapy resistance. Dr Richard Chen, chief medical officer, said the innovation aims to inform patient management once cancer recurrence is detected.

Business Wire
Mar 17th, 2026
Personalis appoints Dr. Richard Chen as President to further accelerate MRD adoption.

Personalis appoints Dr. Richard Chen as President to further accelerate MRD adoption. Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing FREMONT, Calif.-(BUSINESS WIRE)-Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific leadership, Personalis developed and accelerated adoption of the NeXT Personal(R) platform, which set a new industry benchmark for ultrasensitive MRD testing, detecting cancer at levels far below those previously achievable. "Personalis is no longer just participating in the MRD market; we are defining its future," said Chris Hall, Chief Executive Officer of Personalis. "Rich has been the principal architect of our most significant product and technology leaps, including NeXT Personal, and designed the clinical evidence strategy that has accelerated adoption of our ultrasensitive MRD tests. By elevating him to President, we are aligning our visionary R&D with the need to integrate the technology into pharmaceutical drug trials and physician workflows to help patients fight cancer." As President, Dr. Chen will oversee the integration of the company's R&D capabilities, biopharma services, reimbursement, quality systems and medical affairs to capitalize on the technical excellence of the Personalis platform and accelerate revenue growth. "The work we have done with NeXT Personal has proven that ultra sensitivity is central to enabling earlier detection and intervention for cancer patients, and, just as important, more peace of mind for patients with a negative test result," said Dr. Chen. "We have pioneered a new path in the market and I am excited to step into this expanded role to help lead the scaling of the company. Our goal is clear: to make ultrasensitive MRD testing the standard of care for every cancer patient, ensuring earlier detection and better outcomes." Dr. Chen's promotion reinforces the company's commitment to scientific rigor as it scales its commercial footprint. His deep expertise in genomic medicine and machine learning, and his track record of moving innovative R&D projects into high-growth clinical products, make him the ideal leader to help drive this next phase of the company's evolution. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "believe," "expect," "if," "may," "will" or similar expressions. These statements include those relating to: Personalis' role in defining the future of the MRD market; the expected benefits of aligning research and development capabilities with integration of Personalis' technology into pharmaceutical drug trials and physician workflows, including ultrasensitive MRD testing becoming the standard of care, earlier detection, better outcomes and future revenue growth; and Personalis' market leadership, performance, plans and expectations. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis' ability to demonstrate attributes, advantages or clinical validity or utility of the NeXT Personal test, including the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range; the integration of R&D capabilities, biopharma services, reimbursement, quality systems and medical affairs under Dr. Chen's leadership translating into accelerated revenue growth; the rate of adoption and use of the NeXT Personal test; changes in health care policy, which could increase Personalis' costs, decrease Personalis' revenue, and impact sales of and reimbursement for Personalis' tests; the impact of competition and macroeconomic factors on Personalis' business; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Contacts. Media Contact: Patrick Schmidt [email protected] 630-290-2787 More News From Personalis, Inc. FREMONT, Calif.-( BUSINESS WIRE )-Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease," showed that ultrasensitive molecular residual disease (MRD) testing with NeXT Personal can perform... FREMONT, Calif.-( BUSINESS WIRE )-Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of patients with Stage I to III non-small cell lung cancer (NSCLC). This coverage determination is grounded in clinical evidence generated through the company's collaboration with the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) consortium. Data... FREMONT, Calif.-( BUSINESS WIRE )-Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease (MRD) assay, NeXT Personal(R), in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," wa...

Yahoo Finance
Feb 3rd, 2026
Personalis set for reimbursement decision in Q4 2025 as cancer test shows 98% oncologist retention

Personalis, a cancer genomics company, presents a compelling investment case centred on its NeXT Personal test, a blood-based assay detecting cancer recurrence 12–18 months earlier than traditional imaging. The test tracks up to 1,800 tumour variants, significantly outperforming competitors like Natera's Signatera. Currently contributing under 1% of Personalis' $85 million revenue, NeXT Personal has gained traction with over 600 oncologists and a 98% retention rate. Medicare and private insurer reimbursement, expected in Q4 2025, could trigger a revenue inflection point. An exclusive distribution partnership with Tempus, reaching over half of US oncologists across 2,000-plus hospitals, positions the test for rapid adoption. If NeXT Personal captures 6% market share by 2029, it could generate $100 million in EBIT, implying a $2 billion valuation versus Personalis' current $500 million enterprise value.

TradingView
Nov 28th, 2025
Personalis, Inc. $100M Stock Offering

Personalis, Inc. announced a $100 million common stock offering on November 28, 2025. The announcement was detailed in an SEC filing, specifically an 8-K form.

360Dx
Sep 11th, 2025
Personalis, Yale Launch Trial to Measure Clinical Utility of ctDNA-Guided Breast Cancer Treatment

NEW YORK - Personalis said Wednesday that it has entered a collaboration with the Yale Cancer Center for a clinical trial titled CATE to evaluate a strategy of circulating tumor DNA (ctDNA)-guided treatment in women with hormone receptor-positive HER2-negative breast cancer.

INACTIVE